Cargando…

ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen

Estrogen receptor positive (ER+) breast cancer patients are eligible for hormonal treatment, but only around half respond. A test with higher specificity for prediction of endocrine therapy response is needed to avoid hormonal overtreatment and to enable selection of alternative treatments. A novel...

Descripción completa

Detalles Bibliográficos
Autores principales: M. Sieuwerts, Anieta, A. Inda, Márcia, Smid, Marcel, van Ooijen, Henk, van de Stolpe, Anja, Martens, John W. M., Verhaegh, Wim F. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226576/
https://www.ncbi.nlm.nih.gov/pubmed/32230714
http://dx.doi.org/10.3390/cancers12040802
_version_ 1783534321125031936
author M. Sieuwerts, Anieta
A. Inda, Márcia
Smid, Marcel
van Ooijen, Henk
van de Stolpe, Anja
Martens, John W. M.
Verhaegh, Wim F. J.
author_facet M. Sieuwerts, Anieta
A. Inda, Márcia
Smid, Marcel
van Ooijen, Henk
van de Stolpe, Anja
Martens, John W. M.
Verhaegh, Wim F. J.
author_sort M. Sieuwerts, Anieta
collection PubMed
description Estrogen receptor positive (ER+) breast cancer patients are eligible for hormonal treatment, but only around half respond. A test with higher specificity for prediction of endocrine therapy response is needed to avoid hormonal overtreatment and to enable selection of alternative treatments. A novel testing method was reported before that enables measurement of functional signal transduction pathway activity in individual cancer tissue samples, using mRNA levels of target genes of the respective pathway-specific transcription factor. Using this method, 130 primary breast cancer samples were analyzed from non-metastatic ER+ patients, treated with surgery without adjuvant hormonal therapy, who subsequently developed metastatic disease that was treated with first-line tamoxifen. Quantitative activity levels were measured of androgen and estrogen receptor (AR and ER), PI3K-FOXO, Hedgehog (HH), NFκB, TGFβ, and Wnt pathways. Based on samples with known pathway activity, thresholds were set to distinguish low from high activity. Subsequently, pathway activity levels were correlated with the tamoxifen treatment response and progression-free survival. High ER pathway activity was measured in 41% of the primary tumors and was associated with longer time to progression (PFS) of metastases during first-line tamoxifen treatment. In contrast, high PI3K, HH, and androgen receptor pathway activity was associated with shorter PFS, and high PI3K and TGFβ pathway activity with worse treatment response. Potential clinical utility of assessment of ER pathway activity lies in predicting response to hormonal therapy, while activity of PI3K, HH, TGFβ, and AR pathways may indicate failure to respond, but also opens new avenues for alternative or complementary targeted treatments.
format Online
Article
Text
id pubmed-7226576
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72265762020-05-18 ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen M. Sieuwerts, Anieta A. Inda, Márcia Smid, Marcel van Ooijen, Henk van de Stolpe, Anja Martens, John W. M. Verhaegh, Wim F. J. Cancers (Basel) Article Estrogen receptor positive (ER+) breast cancer patients are eligible for hormonal treatment, but only around half respond. A test with higher specificity for prediction of endocrine therapy response is needed to avoid hormonal overtreatment and to enable selection of alternative treatments. A novel testing method was reported before that enables measurement of functional signal transduction pathway activity in individual cancer tissue samples, using mRNA levels of target genes of the respective pathway-specific transcription factor. Using this method, 130 primary breast cancer samples were analyzed from non-metastatic ER+ patients, treated with surgery without adjuvant hormonal therapy, who subsequently developed metastatic disease that was treated with first-line tamoxifen. Quantitative activity levels were measured of androgen and estrogen receptor (AR and ER), PI3K-FOXO, Hedgehog (HH), NFκB, TGFβ, and Wnt pathways. Based on samples with known pathway activity, thresholds were set to distinguish low from high activity. Subsequently, pathway activity levels were correlated with the tamoxifen treatment response and progression-free survival. High ER pathway activity was measured in 41% of the primary tumors and was associated with longer time to progression (PFS) of metastases during first-line tamoxifen treatment. In contrast, high PI3K, HH, and androgen receptor pathway activity was associated with shorter PFS, and high PI3K and TGFβ pathway activity with worse treatment response. Potential clinical utility of assessment of ER pathway activity lies in predicting response to hormonal therapy, while activity of PI3K, HH, TGFβ, and AR pathways may indicate failure to respond, but also opens new avenues for alternative or complementary targeted treatments. MDPI 2020-03-27 /pmc/articles/PMC7226576/ /pubmed/32230714 http://dx.doi.org/10.3390/cancers12040802 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
M. Sieuwerts, Anieta
A. Inda, Márcia
Smid, Marcel
van Ooijen, Henk
van de Stolpe, Anja
Martens, John W. M.
Verhaegh, Wim F. J.
ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
title ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
title_full ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
title_fullStr ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
title_full_unstemmed ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
title_short ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
title_sort er and pi3k pathway activity in primary er positive breast cancer is associated with progression-free survival of metastatic patients under first-line tamoxifen
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226576/
https://www.ncbi.nlm.nih.gov/pubmed/32230714
http://dx.doi.org/10.3390/cancers12040802
work_keys_str_mv AT msieuwertsanieta erandpi3kpathwayactivityinprimaryerpositivebreastcancerisassociatedwithprogressionfreesurvivalofmetastaticpatientsunderfirstlinetamoxifen
AT aindamarcia erandpi3kpathwayactivityinprimaryerpositivebreastcancerisassociatedwithprogressionfreesurvivalofmetastaticpatientsunderfirstlinetamoxifen
AT smidmarcel erandpi3kpathwayactivityinprimaryerpositivebreastcancerisassociatedwithprogressionfreesurvivalofmetastaticpatientsunderfirstlinetamoxifen
AT vanooijenhenk erandpi3kpathwayactivityinprimaryerpositivebreastcancerisassociatedwithprogressionfreesurvivalofmetastaticpatientsunderfirstlinetamoxifen
AT vandestolpeanja erandpi3kpathwayactivityinprimaryerpositivebreastcancerisassociatedwithprogressionfreesurvivalofmetastaticpatientsunderfirstlinetamoxifen
AT martensjohnwm erandpi3kpathwayactivityinprimaryerpositivebreastcancerisassociatedwithprogressionfreesurvivalofmetastaticpatientsunderfirstlinetamoxifen
AT verhaeghwimfj erandpi3kpathwayactivityinprimaryerpositivebreastcancerisassociatedwithprogressionfreesurvivalofmetastaticpatientsunderfirstlinetamoxifen